BFRI vs. AKTX, GRTX, ADIL, MTEM, AEZS, LGVN, HEPA, ATHE, MBRX, and VIRI
Should you be buying Biofrontera stock or one of its competitors? The main competitors of Biofrontera include Akari Therapeutics (AKTX), Galera Therapeutics (GRTX), Adial Pharmaceuticals (ADIL), Molecular Templates (MTEM), Aeterna Zentaris (AEZS), Longeveron (LGVN), Hepion Pharmaceuticals (HEPA), Alterity Therapeutics (ATHE), Moleculin Biotech (MBRX), and Virios Therapeutics (VIRI). These companies are all part of the "pharmaceutical preparations" industry.
Akari Therapeutics (NASDAQ:AKTX) and Biofrontera (NASDAQ:BFRI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership.
Akari Therapeutics has a net margin of 0.00% compared to Akari Therapeutics' net margin of -59.09%. Biofrontera's return on equity of 0.00% beat Akari Therapeutics' return on equity.
Biofrontera has a consensus target price of $18.00, indicating a potential upside of 1,021.57%. Given Akari Therapeutics' higher possible upside, analysts plainly believe Biofrontera is more favorable than Akari Therapeutics.
Akari Therapeutics has higher earnings, but lower revenue than Biofrontera.
Akari Therapeutics received 256 more outperform votes than Biofrontera when rated by MarketBeat users. However, 60.00% of users gave Biofrontera an outperform vote while only 54.93% of users gave Akari Therapeutics an outperform vote.
5.1% of Akari Therapeutics shares are owned by institutional investors. Comparatively, 10.1% of Biofrontera shares are owned by institutional investors. 61.8% of Akari Therapeutics shares are owned by insiders. Comparatively, 0.7% of Biofrontera shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Akari Therapeutics has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Biofrontera has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.
In the previous week, Akari Therapeutics had 1 more articles in the media than Biofrontera. MarketBeat recorded 2 mentions for Akari Therapeutics and 1 mentions for Biofrontera. Biofrontera's average media sentiment score of 0.50 beat Akari Therapeutics' score of 0.00 indicating that Akari Therapeutics is being referred to more favorably in the media.
Summary
Akari Therapeutics beats Biofrontera on 9 of the 14 factors compared between the two stocks.
Get Biofrontera News Delivered to You Automatically
Sign up to receive the latest news and ratings for BFRI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BFRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biofrontera Competitors List
Related Companies and Tools
